CN114796528A - Tumor specific targeting polypeptide and application thereof - Google Patents

Tumor specific targeting polypeptide and application thereof Download PDF

Info

Publication number
CN114796528A
CN114796528A CN202210359385.5A CN202210359385A CN114796528A CN 114796528 A CN114796528 A CN 114796528A CN 202210359385 A CN202210359385 A CN 202210359385A CN 114796528 A CN114796528 A CN 114796528A
Authority
CN
China
Prior art keywords
tumor
imaging
yqga
hynic
spect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210359385.5A
Other languages
Chinese (zh)
Other versions
CN114796528B (en
Inventor
顾月清
涂远彪
刘培飞
王芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN202210359385.5A priority Critical patent/CN114796528B/en
Publication of CN114796528A publication Critical patent/CN114796528A/en
Application granted granted Critical
Publication of CN114796528B publication Critical patent/CN114796528B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses a tumor specific targeting polypeptide and application thereof. The series of high affinity polypeptides of the invention can be specifically combined with a plurality of tumor cells, and can be used for optical imaging and nuclear medicine imaging of malignant tumors by utilizing the high affinity characteristic. The high-affinity polypeptide-coupled fluorescent dye can be used as a tumor specific targeting molecular probe, is expected to achieve the effect of accurately positioning a tumor boundary, can bring real-time performance to image navigation before and during operation, and has the advantage of improving the operation accuracy. The series of polypeptides can also be coupled with radionuclide to detect malignant tumors in real time in vivo so as to achieve the purpose of disease diagnosis or treatment.

Description

Tumor specific targeting polypeptide and application thereof
Description of the cases
The application is divided application with application date of 2020, 05 and 11, application number of 202010392677X, and name of the invention being tumor targeting polypeptide and application thereof.
Technical Field
The invention belongs to the technical field of bioengineering pharmacy and the field of protein polypeptide drugs and biomedical engineering, and particularly relates to a tumor targeting polypeptide and application thereof.
Background
Tumors have become the chief culprit threatening human health and life, and therefore, early diagnosis of tumors and effective treatment of tumors are very important and urgent. For tumors, the conventional image diagnosis technologies mainly include B-ultrasound, CT and MRI, and the image diagnosis technologies achieve diagnosis results by displaying the function change of tissues, have good application value, but have certain defects in differential diagnosis, whole body staging and early curative effect evaluation. Undeniably, screening and optimizing the polypeptide targeting the tumor is a new way, can develop novel molecular imaging drugs for the diagnosis, staging and operation guidance of the tumor, can discover more tiny focuses, and achieves the purpose of early diagnosis.
The cyanine dye has the advantages of small molecular weight, low toxicity, wide wavelength adjustable range, large molar extinction coefficient and the like, so that the cyanine dye is widely applied to the field of fluorescent labeling. The structure of the cyanine dye is modified to be connected with a reactive group with activity, and then the reactive group reacts with amino or carboxyl of a specific target molecule such as an antibody, a protein, a short peptide, a small molecule and the like to form a stable covalent bond, so that a probe with the specific target molecule is formed to perform fluorescent molecule living body imaging, and the fluorescent molecule living body imaging method is an important application of the near-infrared fluorescent dye. Single-Photon emission computed tomography (SPECT-CT) is a novel nuclear medicine imaging technology developed in recent 20 years and popularized clinically, mainly utilizes short-half-life radionuclide to mark a ligand with specific targeting for tracing and imaging, can display information such as substance metabolism, cell proliferation and receptor distribution in vivo, and is used for diagnosis of diseases and research of human body life activities. Therefore, specifically targeted ligands are critical for fluorescence imaging as well as radionuclide imaging.
Based on the consideration, the applicant designs a novel tumor targeting polypeptide, the polypeptide can specifically target tumors, and the coupled fluorescent dye can be used for optical imaging to assist doctors in accurately positioning tumor boundaries in the operation when molecular imaging operation navigation equipment is used, so that the aim of accurately cutting off the tumors is fulfilled, the wound on a patient is reduced, and the risk of postoperative recurrence is reduced. In addition, the targeted polypeptide can be coupled with radionuclide to carry out nuclide imaging, thereby achieving the purposes of early diagnosis and treatment of tumors.
Disclosure of Invention
The invention aims at providing several polypeptides with novel structure and tumor specificity target and sequences thereof;
the invention also aims to provide a preparation method of several tumor-specific targeted fluorescent probes;
the invention also aims to provide a preparation method of a plurality of tumor-specific targeting radioactive probes;
it is a further object of the invention to provide several of the described probes for use in optical and SPECT imaging.
A tumor-specific targeting polypeptide selected from any one of the following polypeptides:
YQGA-2：D-Asp-Arg-Val-Tyr-Ile-His-Pro-D-Phe
YQGA-3：D-Asp-homoArg-Nva-(3-I-Tyr)-Nle-His-Hyp-(4-F-Phe)
YQGA-4：[Sar]-homoArg-Nva-(3-Cl-Tyr)-Nle-His-Hyp-Nle
YQGA-5：D-Asp-Arg-Val-Tyr-NH 2
YQGA-6：D-Asp-homoArg-Nva-Tyr-NH 2
YQGA-7：D-Asp-homoArg-Nva-(4-OCH 3 -Phe)
YQGA-8：Asp-homoArg-Nva-Tyr-NH 2
YQGA-9: Mpa-D-Asp-Arg-Val-Tyr-Lys-Cys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-10: Mpa-D-Asp-Arg-Val-Tyr-Cys-Lys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-11: beta-Ala-D-Asp-Arg-Val-Tyr-Lys-Asp (beta-Ala amino group and Asp backbone carboxyl group forming a ring)
YQGA-12: beta-Ala-D-Asp-Arg-Val-Tyr-Asp-Lys (beta-Ala amino and Asp backbone carboxyl forming a ring)
Wherein: D-Asp: d-aspartic acid; homoArg: homoarginine; nva: norvaline; nle: norleucine; hyp: hydroxyproline; 4-F-Phe: 4-fluoro-phenylalanine; 4-OCH 3 -Phe: 4-fluoro-phenylalanine; [ Sar)]: n-methylglycine; 3-Cl-Try: 3-chloro-tyrosine; 3-I-Try: 3-iodo-tyrosine; mpa: 3-mercaptopropionic acid.
The application of the tumor-specific targeted polypeptide in preparing a tumor diagnosis reagent is preferably the application in preparing a tumor diagnosis imaging agent; further preferably in the preparation of precise localization of tumor boundaries and intraoperative image-guided imaging reagents or the preparation of radionuclide imaging reagents; the tumor-specific targeting polypeptide is selected from any one of the following polypeptides:
YQGA-1：Asp-Arg-Val-Tyr-Ile-His-Pro-Phe
YQGA-2：D-Asp-Arg-Val-Tyr-Ile-His-Pro-D-Phe
YQGA-3：D-Asp-homoArg-Nva-(3-I-Tyr)-Nle-His-Hyp-(4-F-Phe)
YQGA-4：[Sar]-homoArg-Nva-(3-Cl-Tyr)-Nle-His-Hyp-Nle
YQGA-5：D-Asp-Arg-Val-Tyr-NH 2
YQGA-6：D-Asp-homoArg-Nva-Tyr-NH 2
YQGA-7：D-Asp-homoArg-Nva-(4-OCH 3 -Phe)
YQGA-8：Asp-homoArg-Nva-Tyr-NH 2
YQGA-9: Mpa-D-Asp-Arg-Val-Tyr-Lys-Cys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-10: Mpa-D-Asp-Arg-Val-Tyr-Cys-Lys, wherein the MPA-Cys disulfide bond forms a ring;
YQGA-11: beta-Ala-D-Asp-Arg-Val-Tyr-Lys-Asp (beta-Ala amino group and Asp backbone carboxyl group forming a ring)
YQGA-12: beta-Ala-D-Asp-Arg-Val-Tyr-Asp-Lys (beta-Ala amino and Asp backbone carboxyl forming a ring)
Wherein: D-Asp: d-aspartic acid; homoArg: homoarginine; nva: norvaline; nle: norleucine; hyp: hydroxyproline; 4-F-Phe: 4-fluoro-phenylalanine; 4-OCH 3 -Phe: 4-fluoro-phenylalanine; [ Sar)]: n-methylglycine; 3-Cl-Try: 3-chloro-tyrosine; 3-I-Try: 3-iodo-tyrosine; mpa: 3-mercaptopropionic acid.
A polypeptide compound with tumor-targeted fluorescence imaging function contains a polypeptide for targeting tumor and an infrared fluorescent dye structure for optical imaging, and the structural general formula of the polypeptide compound is shown as the following formula (I):
Figure BDA0003584397380000031
the structure of the polypeptide contains a polypeptide R for targeting tumor, a near-infrared fluorescent dye structure MPA for optical imaging and a connecting agent L which can increase the distance between the targeting polypeptide and the near-infrared fluorescent dye and adjust the in vivo pharmacokinetic characteristic.
The polypeptide R is selected from any one of the above tumor-specific targeting polypeptides YQGA-X (X ═ 1-12) of the present invention.
The drug linking agent L is selected from L1, L2, L3 and L4 shown in a structural formula (II);
L 1
Figure BDA0003584397380000041
L 2
Figure BDA0003584397380000042
L3
Figure BDA0003584397380000043
L 4
Figure BDA0003584397380000044
the invention also provides a method for preparing the polypeptide fluorescent probe, which comprises the following steps:
1) synthesis of near-infrared fluorescent dye MPA
Glacial acetic acid, p-hydrazino benzenesulfonic acid, methyl isopropyl ketone and sodium acetate are mixed and reacted, and a product 2,2, 3-trimethyl [3H ] -indole-5-sulfonic acid is obtained after purification; and adding o-dichlorobenzene into the mixture of 2,2, 3-trimethyl [3H ] -indole-5-sulfonic acid and 1, 3-propane sulfonic lactone to prepare the 2,2, 3-trimethyl-5-sulfonic acid-1- (3-sulfonic acid-propyl) - [3H ] -indole. And then reacting the product with N- [ (3- (anilomethylene) -2-chloro-1-cyclohexen-1-yl) methyl ] -aniline monohydrochloride to obtain green carbocyanine dye, and finally reacting the carbocyanine dye with mercaptopropionic acid and triethylamine to prepare a liquid phase, and separating and purifying the liquid phase to obtain the water-soluble near-infrared dye MPA.
2) Synthesis of MPA-L-YQGA-X (X. sub.1-12)
And dissolving the separated and purified near-infrared dye MPA and L-YQGA-X (X ═ 1-12) polypeptide synthesized by a solid phase in dimethyl sulfoxide, adding a proper amount of N, N-Diisopropylethylamine (DIPEA), reacting at room temperature overnight, and after the reaction is finished, purifying and separating a prepared liquid phase to obtain the target fluorescent compound.
The invention relates to the application of the polypeptide compound with the tumor-targeted fluorescence imaging function in the preparation of tumor diagnostic reagents; preferably in the preparation of an imaging agent for tumor diagnosis; further preferably in the preparation of a precise localization of tumor boundaries and intra-operative image-navigation imaging agent or in the preparation of a radionuclide imaging agent.
On the basis, the invention further provides a radionuclide probe which is a monomeric polypeptide complex and a dimeric polypeptide complex labeled by radionuclide technetium, and the structural formulas are shown as (III), (IV) and (V):
Figure BDA0003584397380000051
the monomer form of the targeting complex is simpler to prepare than the dimer form, the dimer structure of the targeting complex contains polypeptide YQGA-X for targeting tumors and a bifunctional chelating agent 6-hydrazinopyridine-3-formic acid (HYNIC) for radioactive labeling, a bracket (3L-E) of glutamic acid connected with a trimolecular connecting agent L, and the connecting agent L which plays a role in increasing the distance between the targeting polypeptide and radionuclide ligands N-tris (hydroxymethyl) methylglycine (Tricine) and triphenylphosphine sodium tri-metaphosphate (TPPTS) and adjusting the in vivo pharmacokinetic characteristics, wherein L is selected from L1, L2, L3 and L4. Wherein the bifunctional chelating agent is modified, e.g. replaced by a bifunctional chelating agent such as DOTA, NOTA, MAG 3 Or DTPA, optionally with radionuclides 99m Radionuclides other than Tc, e.g. 68 Ga， 64 Cu， 67 Ga， 90 Y， 111 In or 177 Lu is used for diagnosis or treatment of diseases.
The invention also provides a method for preparing the monomer and dimer radionuclide probes, which comprises the following steps:
1) synthesis of bifunctional chelating agent HYNIC-L-NHS
Adding 6-chloronicotinic acid and 80% hydrazine hydrate into ethanol, heating and refluxing for reaction, performing rotary evaporation on the solvent under reduced pressure after the reaction is finished, adding the obtained viscous substance into distilled water, adjusting the pH value to be about 5.5, separating out solid, performing suction filtration and drying to obtain yellow solid, and determining the product as 6-hydrazinonicotinic acid through ESI-MS mass spectrum and nuclear magnetic hydrogen spectrum. Adding the obtained 6-hydrazinonicotinic acid and p-aminobenzaldehyde into dimethyl sulfoxide (DMSO), heating for reaction for 5-6 hours, adding into water for precipitation after the reaction is finished, performing suction filtration to obtain a solid, adding the dried solid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and N-hydroxysuccinimide (NHS) into the DMSO for reaction at room temperature, adding into water for precipitation after the reaction is finished, purifying the solid through a silica gel column, determining the solid as an intermediate HYNIC-NHS through ESI-MS mass spectrometry and nuclear magnetic hydrogen spectrometry, reacting the intermediate with a linking agent L under an alkaline condition, finally activating with activating agents EDCI and NHS, and purifying to obtain a HYNIC-L-NHS solid for later use.
2) Synthesis of scaffold (2L-E)
Dissolving a proper amount of Boc-glutamic acid in DMSO, adding 2 times of molar amount of EDCI and NHS, heating at 60 ℃ for 30min, analyzing the generation of glutamic acid double-activated ester by HPLC, adding 2 times of molar amount of linker L and 3 times of molar amount of DIPEA, heating at 60 ℃ for 30min, analyzing 2 PEG by HPLC 4 The molecule is connected with glutamic acid, then equal volume of TFA is added to react at room temperature overnight to remove Boc protection, and finally the crude product is frozen and dried for standby after being separated by a preparation liquid phase.
3) Synthesis of intermediate 3L-E-HYNIC-NHS
Dissolving the prepared scaffold 2L-E in DMSO, adding HYNIC-L-NHS with the same molar weight, adding 3 times of DIPEA, reacting at room temperature for 2 hours, separating and purifying the prepared liquid phase after the reaction is finished, confirming a target compound through mass spectrometry, activating the purified product by EDCI and NHS, and purifying to obtain 3L-E-HYNIC-NHS for later use.
4)(YQGA-X) 2 Synthesis of (E) -3L-HYNIC
Dissolving the purified intermediate 3L-E-HYNIC-NHS in DMSO, adding 0.5 molar amount of targeting peptide YQG-X, then adding 2 molar amount of DIPEA, reacting at room temperature for 1 hour, and separating and purifying by a preparation liquid phase after the reaction is finished and confirming by mass spectrum.
5) Radioactive probe 99m Tc-HYNIC-3L-E-(YQGA-X) 2 Synthesis of (2)
TPPTS (Triphenyl sodium Tri-metaphosphate) solution with the concentration of 100.0mg/mL, Tricine (trimethylglycine) with the concentration of 130.0mg/mL, succinic acid-sodium succinate buffer solution with the concentration of 102.4mg/mL (wherein the succinic acid is 77.0mg, and the sodium succinate is 25.4mg) are respectively prepared, 10.0uL TPPTS solution, 10.0uL Tricine solution, 10.0uL succinic acid-sodium succinate buffer solution and 10.0uL (1.0mg/mL) HYNIC-3L-E- (YQGA-X) are respectively taken 2 Mixing in penicillin bottle, adding 10mCi Na 99m TcO 4 Heating in metal bath at 100 deg.C for 20 minAfter the reaction is finished, cooling to room temperature, respectively preparing the polypeptide radiopharmaceuticals, and analyzing and identifying the products by an Agilent ZORBAX SB-Aq analytical column.
The radionuclide probe is applied to the preparation of tumor diagnostic reagents; preferably in the preparation of an imaging agent for tumor diagnosis; further preferably in the preparation of a precise localization of tumor boundaries and intra-operative image-navigation imaging agent or in the preparation of a radionuclide imaging agent.
The polypeptide compound can be specifically targeted to a tumor part, has good uptake and retention capacity at the tumor part, has a high target/non-target ratio, is suitable for being used as a fluorescent tumor imaging agent, a radionuclide imaging agent and a therapeutic agent, and can be used for preparing an optical imaging medicament for image navigation and accurate positioning of tumor boundaries in a tumor operation.
Compared with the prior art, the novel polypeptide and the fluorescent and radionuclide probes constructed by the series of polypeptides have the beneficial effects that:
1. the YQGA-X series of polypeptides found by the invention are low molecular weight polypeptides, and a plurality of or more amino acids of the series of polypeptides are modified unnatural amino acids, and the introduction of the unnatural amino acids can greatly improve the stability of the series of polypeptides in vivo.
2. The YQGA-X series of polypeptides are proved to have excellent imaging effect on various tumors including liver cancer, lung cancer, breast cancer, pancreatic cancer, colorectal cancer, cervical cancer and the like through in vivo optics and radionuclide imaging results. The probe constructed by the series of polypeptides can specifically target the property of a tumor part, and can possibly realize nuclear medicine diagnosis, treatment and optical imaging of malignant tumors to guide surgeons to perform operation navigation, so that the focus is accurately removed.
3. The invention uses the near-infrared fluorescent dye MPA with more ideal stability and water solubility as an optical imaging group, and improves the pharmacokinetics of the medicament in vivo.
4. In the invention, a plurality of water-soluble PEG are introduced 4 Or PEG 6 Molecules to further improve pharmacokinetic properties, in particularKinetics of clearance from non-tumor tissue.
5. In the invention, HYNIC is used as a bifunctional chelating agent, and Tricine and TPPTS are simultaneously used as synergistic ligands, so that " 99m Tc-HYNIC nucleus has better in vivo and in vitro stability.
The invention is further explained with reference to the drawings and the embodiments.
Drawings
FIG. 1 shows the fluorescent compound MPA-PEG prepared in example 1 4 Fluorescence imaging of YQGA-1 in hepatoma HepG2 tumor-bearing mice.
FIG. 2 is prepared as in example 2 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-1 in liver cancer HepG2 tumor-bearing mice (A) and brain glioma U87MG tumor-bearing mice (B).
FIG. 3 shows the radioactive compound prepared in example 4 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in tumor-bearing mice: a is SPECT-CT imaging in a liver cancer HepG2 tumor-bearing mouse, B is SPECT-CT imaging in a cervical cancer HeLa tumor-bearing mouse, C is SPECT-CT imaging in a breast cancer MCF-7 tumor-bearing mouse, and D is SPECT-CT imaging in a liver cancer MHCC97-H tumor-bearing mouse.
FIG. 4 shows the radioactive compound prepared in example 8 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-3 in hepatoma HepG2 tumor-bearing mice.
FIG. 5 shows the radioactive compound prepared in example 9 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-4 in hepatoma HepG2 tumor-bearing mice.
FIG. 6 shows the radioactive compound prepared in example 10 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in tumor-bearing mice: SPECT-CT imaging of A in liver cancer HepG2 tumor-bearing mice; b, SPECT-CT imaging in a liver cancer MHCC97-H tumor-bearing mouse; c SPECT-CT imaging in a cervical cancer HeLa tumor-bearing mouse; SPECT-CT imaging in breast cancer MCF-7 tumor-bearing mice.
FIG. 7 shows the radioactive compound prepared in example 14 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in tumor-bearing mice: a is in liver cancer HepG 2; b is SPECT-CT imaging in a cervical cancer HeLa tumor-bearing mouse;c is SPECT-CT imaging in lung cancer A549 tumor-bearing mice; d is SPECT-CT imaging in a breast cancer MCF-7 tumor-bearing mouse; SPECT-CT imaging in mice bearing SW1990 tumors in pancreatic cancer; f is SPECT-CT imaging in colorectal cancer HT29 tumor-bearing mice; g is SPECT-CT imaging in neuroendocrine tumor BON-1 tumor-bearing mice.
FIG. 8 shows the radioactive compound prepared in example 14 99m Tc-HYNIC-YQGA-6 in-situ colorectal cancer tumor-bearing mouse 1h18min SPECT-CT imaging result
FIG. 9 shows the radioactive compound prepared in example 22 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 SPECT-CT imaging in pancreatic cancer CFPAC-1 tumor-bearing mice.
FIG. 10 is a fluorescence image of the fluorescent compound MPA-Aca-YQGA-6 prepared in example 23 in tumor-bearing mice: a is fluorescence imaging in a liver cancer HepG2 tumor-bearing mouse; b is fluorescence imaging in breast cancer MCF-7 tumor-bearing mice.
FIG. 11 shows the radioactive compound prepared in example 25 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-7 in mice bearing HeLa tumors of cervical carcinoma.
FIG. 12 shows the radioactive compound prepared in example 26 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-8 in tumor-bearing mice: a is SPECT-CT imaging in a liver cancer HepG2 tumor-bearing mouse; b is SPECT-CT imaging in pancreatic cancer CFPAC-1 tumor-bearing mice.
FIG. 13 shows the radioactive compound prepared in example 28 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-9 in mice bearing MCF-7 tumors for breast cancer.
FIG. 14 shows the radioactive compound prepared in example 29 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-10 in mice bearing SW1190 tumors of pancreatic cancer.
FIG. 15 shows the radioactive compound prepared in example 30 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-11 in hepatoma HepG2 tumor-bearing mice.
FIG. 16 shows the radioactive compound prepared in example 31 99m Tc-HYNIC-PEG 4 SPE of YQGA-12 in breast cancer MCF-7 tumor-bearing miceAnd (4) CT-CT imaging.
Detailed Description
The invention is further illustrated by the following specific examples and application examples: wherein the chemical substances used in the synthesis steps are all the existing substances or commercial products. The polypeptides involved in each example were synthesized by Hangzhou Guotu Biotech Co.
Fluorescent Compound MPA-PEG prepared in example 1 4 Fluorescence imaging of YQGA-1 in hepatoma HepG2 tumor-bearing mice
Weighing PEG synthesized by Commission Hangzhou Gutou Biotech Co 4 -YQGA-1 Compound 10mg, prepared pure dye MPA 12.38mg is added to 200. mu.L of dimethyl sulfoxide (DMSO), then 2.3mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 3.82mg of N-hydroxysuccinimide (NHS) are added, after mixing, 4.1mg of N, N-Diisopropylethylamine (DIPEA) is added, the mixture is reacted overnight at room temperature, and after the reaction is completed, separation and purification are carried out by using a preparative liquid phase, the conditions of the preparative liquid phase are as follows: an Agilent 1220Infinity II series HPLC system was used with an Agilent ZORBAX SB-C18 semi-preparative column (9.4X 250mm, 5um) gradient elution for 60 minutes at a flow rate of 2mL/min, where mobile phase A was ultrapure water (0.01% TFA) and B was acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 80% A and 20% B at 15 min, 50% A and 50% B at 45 min, 5% A and 95% B at 60 min. The green product obtained finally is analyzed by analytical HPLC and ESI-MS mass spectrometry to confirm that the expected product MPA-PEG is obtained 4 -YQGA-1，ESI-MS：[M-3H] 3- 728.42 and [ M-4H] 4- 546.21. In the above preparation process, the YQGA-X or L-YQGA-X polypeptide synthesized in solid phase is used in place of PEG used in the step 4 YQGA-1 polypeptide, namely obtaining other fluorescent polypeptide compounds of the invention. Prepared compound MPA-PEG 4 YQGA-1 and prepared into a physiological saline solution (100nmol/mL), 0.1mL (about 10nmol) is respectively injected into tail veins of 3 nude mice (body weight about 22 g) with hepatoma HepG2 tumor, and optical signal acquisition is carried out at 1h, 2h, 4h, 8h, 10h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. Compound MPA-PEG 4 The imaging results of YQGA-1 in 3 tumor-bearing nude mice are basically consistent, and from the 2h imaging graph, it can be seen that the probe has significant uptake in the tumor, and it can be concluded that the probe is mainly metabolized through the kidney.
Radioactive compound prepared in example 2 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-1 in hepatoma HepG2 tumor-bearing mice
1) Bifunctional chelating agent HYNIC-PEG 4 Synthesis of-NHS
Adding 1g of 6-chloronicotinic acid and 2.0mL of 80% hydrazine hydrate into 10mL of ethanol, heating, refluxing and reacting for 4 hours, decompressing and rotary evaporating a solvent after the reaction is finished, adding the obtained sticky substance into distilled water, adjusting the pH value to be about 5.5, separating out a solid, carrying out suction filtration and drying to obtain 0.86g of a yellow solid, and determining the product to be 6-hydrazinonicotinic acid through ESI-MS mass spectrometry and nuclear magnetic hydrogen spectrometry. Adding 0.86g of the obtained 6-hydrazinonicotinic acid and 0.61g of p-aminobenzaldehyde into 3.0mL of dimethyl sulfoxide (DMSO), heating for reacting for 5-6 hours, adding into water after the reaction is finished, separating out, performing suction filtration, and drying to obtain 1.2g of solid. After drying 1.2g of the solid, 2.5g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 1.5g N-hydroxysuccinimide (NHS) were added into DMSO for reaction at room temperature, after the reaction was completed, water was added to the DMSO to precipitate a solid, the solid was purified by silica gel column and dried, 1.3g was weighed, and ESI-MS mass spectrometry and NMR spectrometry were carried out to determine the target product, ESI-MS: [ M + H ]]382.1508. This product was purified and 1 molar amount of PEG was added 4 And after the reaction is finished, adding EDCI and NHS with 2 times of molar weight for activation, performing freeze-drying after purification, and verifying the product as a target product by mass spectrum, ESI-MS: [ M + H ]]630.3 and [ M + Na]＝652.3。
2) Purified 5mg intermediate HYNIC-PEG 4 -NHS was dissolved in 0.3mL DMSO, then 5mg YQGA-1 was added, then 5.6mg DIPEA was added, and the reaction was performed at room temperature for 3 hours, and the product was separated and purified by preparative liquid phase after completion of the reaction to finally obtain 2.8mg of yellow solid, which was confirmed as a target product by mass spectrometry, ESI-MS: [ M +2H ]] 2+ 780.1 and [ M +3H ═] 3+ ＝520.5。
3) Radioactive compound 99m Tc-HYNIC-PEG 4 Synthesis of (E) -YQGA-1
TPPTS (Triphenyl sodium Tri-metaphosphate) solution with the concentration of 100.0mg/mL, Tricine (trimethylglycine) with the concentration of 130.0mg/mL, succinic acid-sodium succinate buffer solution with the concentration of 102.4mg/mL (wherein the succinic acid is 77.0mg, and the sodium succinate is 25.4mg) are respectively prepared, 10.0uL TPPTS solution, 10.0uL Tricine solution, 10.0uL succinic acid-sodium succinate buffer solution and 10.0uL (1.0mg/mL) HYNIC-PEG are respectively taken 4 Mixing YQGA-1 in penicillin bottle, and adding 10mCi Na 99m TcO 4 Heating in 100 deg.C metal bath for 20 min, cooling to room temperature after reaction to obtain polypeptide radiopharmaceutical 99m Tc-HYNIC-PEG 4 YQGA-1, the product was analyzed and identified by Agilent ZORBAX SB-Aq analytical column. The HPLC method used was an Agilent 1220Infinity II series HPLC system equipped with an active on-line detector (Flow-RAM) and an Agilent ZORBAX SB-Aq analytical column (4.6X 250mm, 5 um). Gradient elution is carried out for 45 minutes at a flow rate of 1mL/min, wherein the mobile phase A is ultrapure water (0.01% TFA) and the mobile phase B is acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 70% A and 30% B at 15 min, 65% A and 35% B at 20 min, 45% A and 55% B at 25 min, 5% A and 95% B at 45 min.
4) Radioactive compound 99m Tc-HYNIC-PEG 4 YQGA-1 is prepared into a physiological saline solution (3mCi/mL), 0.1mL (about 300 mu Ci) is respectively injected into the tail veins of 3 nude mice with liver cancer HepG2 tumor, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h, 3h and 4h after administration. The distribution of the radionuclide probes in the mice and the enrichment in the tumor area were observed. The 1.5h visualization result is shown in FIG. 2A, from which it can be seen that the probe 99m Tc-HYNIC-PEG 4 YQGA-1 has obvious aggregation at the tumor site, which indicates that the probe can target liver cancer HepG2 tumor and is mainly metabolized out of body through kidney.
Radioactive compound prepared in example 3 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-1 in brain glioma U87MG tumor-bearing mice
Radioactive compound prepared in example 2 99m Tc-HYNIC-PEG 4 YQGA-1 and formulated into physiological saline solution (3mCi/mL), 0.1mL (about 300. mu. Ci) was injected into 3 brains, respectivelyGlioma U87MG tumor-bearing nude mice, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 2B, and it can be seen from the figure that the probe can be targeted to recognize brain glioma U87 MG.
Radioactive compound prepared in example 4 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-YQGA-2(HYNIC-YQGA-2 verified by mass spectrum, ESI-MS: [ M + 2H)] 2+ 657.0 and [ M +3H] 3+ 438.5). In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition is carried out 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 3A, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 5 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in cervical carcinoma HeLa bearing mice
In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in fig. 3B, and the probe can be seen in the image to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 6 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in breast cancer MCF-7 bearing mice
In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 nude mice with liver cancer MCF-7 tumor, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 3C, and the figure shows that the probe can identify the MCF-7 tumor of the breast cancer in a targeted mode.
EXAMPLE 7 preparation ofPreparation of radioactive compounds 99m SPECT-CT imaging of Tc-HYNIC-YQGA-2 in MHCC97-H tumor mouse of liver cancer
In the same manner as in example 3 99m Tc-HYNIC-YQGA-2 is respectively injected into 3 liver cancer MHCC97-H tumor-bearing nude mice, and SPECT-CT signal acquisition is carried out 0.5H, 1H, 2H and 4H after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1H SPECT-CT imaging result is shown in FIG. 3D, and it can be seen from the figure that the probe can target and identify MHCC97-H tumor of liver cancer.
Radioactive compound prepared in example 8 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-3 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-3(HYNIC-PEG 4 The mass spectrum of-YQGA-3 proves that ESI-MS shows that [ M +2H] 2+ 866.5 and [ M +3H] 3+ 577.6). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-3 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 4, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 9 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-4 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-4(HYNIC-PEG 4 The mass spectrum of-YQGA-4 proves that ESI-MS shows that [ M +2H] 2+ 772.8 and [ M +3H] 3+ 515.2). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-4 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 5, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Example 10 preparation of radiationSex compound 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of radioactive Compound 99m Tc-HYNIC-PEG 4 -YQGA-5(HYNIC-PEG 4 The mass spectrum of-YQGA-5 proves that ESI-MS shows that [ M +2H] 2+ 509.6 and [ M +3H] 3+ 339.7). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1.5h SPECT-CT imaging result is shown in FIG. 6A, and it can be seen from the graph that the probe can target and identify liver cancer HepG2 tumor.
Radioactive compound prepared in example 11 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in MHCC97-H hepatoma bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 was injected into 3 mice bearing MHCC97-H tumor from liver cancer, and SPECT-CT signal acquisition was performed at 0.5H, 1H, 2H and 4H after administration. The distribution of the probe in the mouse and the enrichment in the tumor area were observed. The 1H SPECT-CT imaging result is shown in FIG. 6B, and it can be seen from the figure that the probe can target and identify MHCC97-H tumor of liver cancer.
Radioactive compound prepared in example 12 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in mice bearing HeLa tumors for cervical cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 -YQGA-5 was injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 6C, and the probe can be seen in the figure to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 13 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-5 in mice bearing MCF-7 tumors for breast cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-5 was injected into 3 breast cancer MCF-7 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 6D, and the probe can be seen in the figure to identify the MCF-7 tumor of the breast cancer in a targeted manner.
Radioactive compound prepared in example 14 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-6(HYNIC-PEG 4 The mass spectrum of-YQGA-6 proves that ESI-MS shows that [ M +2H] 2+ 539.9 and [ M +3H] 3+ 360.3). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1.5h SPECT-CT imaging result is shown in FIG. 7A, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 15 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in mice bearing HeLa tumors for cervical carcinoma
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 is respectively injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition is carried out at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in fig. 7B, and the probe can be seen in the image to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 16 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in Lung cancer A549 tumor-bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 lung cancer A549 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. Observing the probe in the body of the mouseDistribution and enrichment in the tumor area. The 1h SPECT-CT imaging result is shown in FIG. 7C, and it can be seen from the figure that the probe can target and identify the lung cancer A549 tumor.
Radioactive compound prepared in example 17 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in mice bearing MCF-7 tumors for breast cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 lung cancer A549 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 7D, and the graph shows that the probe can identify the MCF-7 tumor of the breast cancer in a targeted mode.
Radioactive compound prepared in example 18 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in mice bearing SW1990 tumors in pancreatic cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 pancreatic cancer SW1990 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging results are shown in FIG. 7E, from which it can be seen that the probe can target the SW1990 tumor, which is recognized as a pancreatic cancer.
Radioactive compound prepared in example 19 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in colorectal cancer HT29 tumor-bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 colorectal cancer HT29 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 7F, and the probe can be seen in the figure to be targeted and identify the colorectal cancer HT29 tumor.
Radioactive compound prepared in example 20 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in neuroendocrine BON-1 tumor-bearing mice
As in example 3The same method is to 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 neuroendocrine tumor BON-1 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probe in the mouse and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 7G, and it can be seen from the figure that the probe can target and identify the tumor of the neuroendocrine tumor BON-1.
Radioactive compound prepared in example 21 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-6 in situ colorectal cancer bearing mice
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-6 was injected into 3 tumor-bearing nude mice with colorectal cancer in situ, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 18min, 2h and 4h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The SPECT-CT imaging result at 1h and 18min is shown in figure 8, and the probe can be seen from the figure to identify colorectal cancer tumor in situ in a targeted manner.
Radioactive compound prepared in example 22 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 SPECT-CT imaging in pancreatic cancer CFPAC-1 bearing mice
Prepared radiopharmaceuticals 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 The synthesis steps are as follows:
1) bifunctional chelating agent HYNIC-PEG 4 Synthesis of-NHS
Adding 1g of 6-chloronicotinic acid and 2.0mL of 80% hydrazine hydrate into 10mL of ethanol, heating, refluxing and reacting for 4 hours, decompressing and rotary evaporating a solvent after the reaction is finished, adding the obtained sticky substance into distilled water, adjusting the pH value to be about 5.5, separating out a solid, carrying out suction filtration and drying to obtain 0.86g of a yellow solid, and determining the product to be 6-hydrazinonicotinic acid through ESI-MS mass spectrometry and nuclear magnetic hydrogen spectrometry. Adding 0.86g of the obtained 6-hydrazinonicotinic acid and 0.61g of p-aminobenzaldehyde into 3.0mL of dimethyl sulfoxide (DMSO), heating for reacting for 5-6 hours, adding into water after the reaction is finished, separating out, performing suction filtration, and drying to obtain 1.2g of solid. 1.2g of this dried solid are then added to DMSO together with 2.5g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 1.5g N-hydroxysuccinimide (NHS)Reacting at room temperature, adding water to precipitate a solid after the reaction is finished, purifying the solid by a silica gel column, drying, weighing 1.3g, determining the solid as a target product by ESI-MS mass spectrum and nuclear magnetic hydrogen spectrum, and adding 1 molar weight of PEG after the product is purified 4 And after the reaction is finished, adding EDCI and NHS with 2 times of molar weight for activation, purifying and freeze-drying for later use.
2) Support (PEG) 4 ) 3 Synthesis of (E)
Adding 5.0g of tert-butyloxycarbonyl (t-Butyloxy carbony) protected glutamic acid, 8.3g of Dicyclohexylcarbodiimide (DCC) and 4.6g N-hydroxysuccinimide (NHS) into 100mL of Tetrahydrofuran (THF), stirring overnight at room temperature for activating the dicarboxyl group, suction-filtering after the reaction is completed, washing the filtrate with THF, directly adding the filtrate into 50mL of dimethyl sulfoxide (DMSO) for dissolution without further purification after the washing is completed, and then adding 10g of PEG 4 Finally, 14.6g of DIPEA is added for reaction at room temperature for 2 hours, after the detection reaction is finished, 3.0mL of trifluoroacetic acid (TEA) is added into the reaction for removing the Boc protecting group, after the reaction is finished, separation and purification are carried out through a preparation liquid phase, and finally drying is carried out to obtain 7.8g of thick solid which is verified to be an expected target object (PEG) through mass spectrum 4 ) 2 -E。
3) Intermediate (PEG) 4 ) 3 Synthesis of-E-HYNIC-2 NHS
0.5g of the prepared scaffold (PEG) 4 ) 2 -E was dissolved in DMSO and 0.31g HYNIC-PEG was added 4 NHS, 0.32g DIPEA was added, the reaction was carried out at room temperature for 2 hours, EDCI and NHS were added for activation, and after completion of the reaction, the product was purified by preparative liquid phase separation and freeze-dried to give 0.34g of a yellow solid, which was confirmed by mass spectrometry as the desired target compound (PEG) 4 ) 3 -E-HYNIC-2NHS，ESI-MS:[M+2H] 2+ 675.5 and [ M +3H] 3+ ＝450.6。
4)HYNIC-3PEG 4 -E-(YQGA-6) 2 Synthesis of (2)
Purified 5mg of intermediate 3PEG 4 Dissolving E-HYNIC-2NHS in 0.3mL DMSO, adding 7.8mg YQGA-6 after reaction, then adding 5.6mg DIPEA, reacting at room temperature for 3 hours, separating and purifying by liquid phase preparation after reaction is finished, and finally obtaining the final productTo a yellow solid of 3.5mg, confirmed by mass spectrometry as the target product, ESI-MS: [ M +3H ]] 3+ 825.7 and [ M +4H] 4+ ＝619.5。
5) 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 Preparation of
TPPTS (Triphenyl sodium Tri-metaphosphate) solution with the concentration of 100.0mg/mL, Tricine (trimethylglycine) with the concentration of 130.0mg/mL, succinic acid-sodium succinate buffer solution with the concentration of 102.4mg/mL (wherein the succinic acid is 77.0mg, and the sodium succinate is 25.4mg) are respectively prepared, 10.0uL TPPTS solution, 10.0uL Tricine solution, 10.0uL succinic acid-sodium succinate buffer solution and 10.0uL (1.0mg/mL) HYNIC-3PEG are respectively taken 4 -E-(YQGA-6) 2 Mixing in penicillin bottle, adding 10mCi Na 99m TcO 4 Heating in 100 deg.C metal bath for 20 min, cooling to room temperature after reaction to obtain polypeptide radiopharmaceutical 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 And analyzing and identifying the product by an Agilent ZORBAX SB-Aq analytical column. The HPLC method used was an Agilent 1220Infinity II series HPLC system equipped with an active on-line detector (Flow-RAM) and an Agilent ZORBAX SB-Aq analytical column (4.6X 250mm, 5 um). Gradient elution is carried out for 45 minutes at a flow rate of 1mL/min, wherein the mobile phase A is ultrapure water (0.01% TFA) and the mobile phase B is acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 70% A and 30% B at 15 min, 65% A and 35% B at 20 min, 45% A and 55% B at 25 min, 5% A and 95% B at 45 min.
6) In the same manner as in example 3 99m Tc-HYNIC-3PEG 4 -E-(YQGA-6) 2 Respectively injecting the three drugs into 3 nude mice with pancreatic cancer CFPAC-1 tumor, and performing SPECT-CT signal acquisition 0.5h, 1h, 2h and 4h after drug administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The result of 1h18min SPECT-CT imaging is shown in FIG. 9, and it can be seen that the probe can target and identify CFPAC-1 tumor of pancreatic cancer.
Fluorescence imaging of the fluorescent Compound MPA-Aca-YQGA-6 prepared in example 23 in hepatoma HepG2 tumor-bearing mice
The fluorescent compound MPA-Aca-YQGA-6 was prepared and formulated into a physiological saline solution (100nmol/mL) as in example 1, and 0.1mL (about 10nmol) was injected into the tail vein of 3 nude mice bearing tumor of HepG2 (body weight: about 22 g), respectively, and optical signal acquisition was performed at 1h, 2h, 4h, 8h, 10h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-Aca-YQGA-6 in 3 tumor-bearing nude mice are basically consistent, and from the 2h imaging graph, the probe is obviously taken up in the tumor, and the probe is deduced to be mainly metabolized through the kidney (FIG. 10A).
Fluorescence imaging of the fluorescent Compound MPA-Aca-YQGA-6 prepared in example 24 in vivo in mice bearing MCF-7 tumor of Breast cancer
The fluorescent compound MPA-Aca-YQGA-6 was prepared and formulated into a physiological saline solution (100nmol/mL) as in example 1, and 0.1mL (about 10nmol) was injected into the tail vein of 3 nude mice bearing breast cancer MCF-7 (body weight: about 22 g), respectively, and optical signal acquisition was performed at 1h, 2h, 4h, 8h, 10h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-Aca-YQGA-6 in 3 tumor-bearing nude mice are basically consistent, and from the 2h imaging graph (FIG. 10B), it can be seen that the probe has obvious uptake in the tumor, and it can be concluded that the probe is mainly metabolized through the kidney.
Radioactive compound prepared in example 25 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-7 in mice bearing HeLa tumors for cervical cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-7(HYNIC-PEG 4 The mass spectrum of-YQGA-7 proves that ESI-MS shows that [ M +2H] 2+ 546.8 and [ M +3H] 3+ 364.5). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 -YQGA-7 was injected into 3 HeLa tumor-bearing nude mice with cervical cancer, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1hSPECT-CT imaging result is shown in figure 11, and the probe can be seen in the figure to identify the HeLa tumor of the cervical cancer in a targeted manner.
Radioactive compound prepared in example 26 99m Tc-HYNIC-PEG 4 YQGA-8 in the liverSPECT-CT imaging in vivo in cancer HepG2 tumor-bearing mice
Preparation of Radioactive Compound in the same manner as in reference example 2 99m Tc-HYNIC-PEG 4 -YQGA-8(HYNIC-PEG 4 The mass spectrum of-YQGA-8 proves that ESI-MS shows that [ M +2H] 2+ 539.8 and [ M +3H] 3+ 360.2). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-8 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probe in the mouse and the enrichment in the tumor area were observed. The result of 1h SPECT-CT imaging is shown in FIG. 12A, and it can be seen that the probe can target and identify HepG2 tumor of liver cancer.
Radioactive compounds prepared in example 27 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-8 in mice bearing CFPAC-1 tumors of pancreatic cancer
In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-8 was injected into 3 CFPAC-1 tumor-bearing nude mice with pancreatic cancer, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 12B, and the probe can be seen in the figure to be targeted to identify CFPAC-1 tumor of pancreatic cancer.
Radioactive compound prepared in example 28 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-9 in mice bearing MCF-7 tumors for breast cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-9(HYNIC-PEG 4 The mass spectrum of-YQGA-9 proves that ESI-MS shows that [ M +2H] 2+ 691.1 and [ M +3H] 3+ 460.6). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-9 was injected into 3 breast cancer MCF-7 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 13, and the probe can be seen in the figure to identify the MCF-7 tumor of the breast cancer in a targeted manner.
Radioactive compound prepared in example 29 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-10 in mice bearing SW1190 tumor of pancreatic cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-10(HYNIC-PEG 4 The mass spectrum of-YQGA-10 proves that ESI-MS shows that [ M +2H] 2+ 691.1 and [ M +3H] 3+ 460.7). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-10 was injected into 3 pancreatic cancer SW1190 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in FIG. 14, and the probe can be seen in the figure to be targeted to and identify SW1190 tumor of pancreatic cancer.
Radioactive compounds prepared in example 30 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-11 in hepatoma HepG2 tumor-bearing mice
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-11(HYNIC-PEG 4 The mass spectrum of-YQGA-11 proves that ESI-MS shows that [ M +2H] 2+ 680.5 and [ M +3H] 3+ 453.6). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-11 was injected into 3 liver cancer HepG2 tumor-bearing nude mice, and SPECT-CT signal acquisition was performed at 0.5h, 1h, 2h and 4h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 15, and the probe can be seen in the figure to identify the liver cancer HepG2 tumor in a targeted manner.
Radioactive compound prepared in example 31 99m Tc-HYNIC-PEG 4 SPECT-CT imaging of YQGA-12 in mice bearing MCF-7 tumors for breast cancer
Reference example 2 preparation of Radioactive Compounds 99m Tc-HYNIC-PEG 4 -YQGA-12(HYNIC-PEG 4 The mass spectrum of-YQGA-12 proves that ESI-MS shows that [ M +2H] 2+ 680.5 and [ M +3H] 3+ 453.5). In the same manner as in example 3 99m Tc-HYNIC-PEG 4 YQGA-12 was injected into 3 mice bearing MCF-7 tumor with breast cancer, and SPECT was performed at 0.5h, 1h, 2h and 4h after administrationAnd (5) acquiring CT signals. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The 1h SPECT-CT imaging result is shown in figure 16, and the probe can be seen in the figure to identify the MCF-7 tumor of the breast cancer in a targeted way.

Claims (10)

1. The application of tumor specific targeting polypeptide in preparing tumor diagnosis reagent, the tumor specific targeting polypeptide:
YQGA-5：D-Asp-Arg-Val-Tyr-NH 2 ；
wherein: D-Asp: d-aspartic acid.
2. Use according to claim 1, characterized in that the use of a tumor-specifically targeted polypeptide according to claim 1 for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.
3. A tumor-specific targeting polypeptide, characterized by being selected from any one of the following polypeptides:
YQGA-5：D-Asp-Arg-Val-Tyr-NH 2 ；
wherein: D-Asp: d-aspartic acid.
4. A polypeptide compound with tumor fluorescence targeting imaging function, which is characterized in that the structure contains the tumor specific targeting polypeptide of claim 1 and an infrared fluorescent dye structure for optical imaging, and the general structural formula is shown as the following formula (I):
Figure FDA0003584397370000011
wherein R is selected from the tumor-specifically targeting polypeptide YQGA-5 of claim 1; l is selected from any one of four shown in the following II;
Figure FDA0003584397370000021
5. the use of the polypeptide compound having tumor-targeted fluorescence imaging function according to claim 4 for the preparation of a tumor diagnostic reagent.
6. The use according to claim 5, characterized in that the use of the polypeptide compound with tumor-targeted fluorescence imaging function according to claim 4 for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.
7. A radionuclide probe characterized by being a polypeptide monomer complex as set forth in claim 1 or a polypeptide dimer complex as set forth in claim 1 labeled with radionuclide technetium; the structural formula is shown as (III), (IV) or (V):
Figure FDA0003584397370000022
or replacing the bifunctional chelating agent HYNIC in the formulas (III), (IV) and (V) by DOTA, NOTA and MAG 3 Or DTPA, radionuclide 99m Tc replacement by 68 Ga， 64 Cu， 67 Ga， 90 Y， 111 In or 177 Lu。
8. The radionuclide probe according to claim 7, characterized in that L is selected from any one or more of L1, L2, L3 or L4.
9. Use of the radionuclide probe according to claim 7 or 8 for the preparation of a tumor diagnostic reagent.
10. Use according to claim 9, characterized in that the radionuclide probe according to claim 7 or 8 is used for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.
CN202210359385.5A 2020-05-11 2020-05-11 Tumor-specific targeting polypeptides and uses thereof Active CN114796528B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210359385.5A CN114796528B (en) 2020-05-11 2020-05-11 Tumor-specific targeting polypeptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010392677.XA CN111558050B (en) 2020-05-11 2020-05-11 Tumor targeting polypeptide and application thereof
CN202210359385.5A CN114796528B (en) 2020-05-11 2020-05-11 Tumor-specific targeting polypeptides and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202010392677.XA Division CN111558050B (en) 2020-05-11 2020-05-11 Tumor targeting polypeptide and application thereof

Publications (2)

Publication Number Publication Date
CN114796528A true CN114796528A (en) 2022-07-29
CN114796528B CN114796528B (en) 2023-11-10

Family

ID=72068047

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202010392677.XA Active CN111558050B (en) 2020-05-11 2020-05-11 Tumor targeting polypeptide and application thereof
CN202210360399.9A Active CN115006553B (en) 2020-05-11 2020-05-11 Polypeptide for preparing tumor diagnostic imaging agent and application thereof
CN202210359401.0A Pending CN115068634A (en) 2020-05-11 2020-05-11 Application of tumor targeting polypeptide
CN202210359385.5A Active CN114796528B (en) 2020-05-11 2020-05-11 Tumor-specific targeting polypeptides and uses thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN202010392677.XA Active CN111558050B (en) 2020-05-11 2020-05-11 Tumor targeting polypeptide and application thereof
CN202210360399.9A Active CN115006553B (en) 2020-05-11 2020-05-11 Polypeptide for preparing tumor diagnostic imaging agent and application thereof
CN202210359401.0A Pending CN115068634A (en) 2020-05-11 2020-05-11 Application of tumor targeting polypeptide

Country Status (1)

Country Link
CN (4) CN111558050B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116407651A (en) * 2023-05-12 2023-07-11 江西省人民医院 Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113209315B (en) * 2021-05-10 2022-11-04 中国医科大学 Polypeptide probe for targeting tumor and application thereof
CN113527416A (en) * 2021-08-11 2021-10-22 南开大学 Preparation method of nitroreductase responsive amino acid and tumor hypoxia fluorescent probe
CN116850307A (en) * 2021-12-16 2023-10-10 江西中医药大学 Application of polypeptide TP-6 in preparation of tumor diagnosis and/or treatment reagent
CN114288426B (en) * 2022-01-07 2023-08-01 江西中医药大学 Application of eribante and derivatives thereof in preparation of tumor diagnosis and/or treatment reagent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901941A (en) * 2003-11-06 2007-01-24 通用电气医疗集团股份有限公司 Conjugates of angiotensin ii and an imaging moiety
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
CN110845572A (en) * 2019-11-28 2020-02-28 中国药科大学 Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100589842C (en) * 2001-01-19 2010-02-17 赛托斯生物技术公司 Molecular antigen array
AU2004241101B2 (en) * 2003-05-15 2010-05-13 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
EP1970064A1 (en) * 2007-03-12 2008-09-17 Bayer Schering Pharma Aktiengesellschaft Silicon-derivatives for pet-imaging
CN101015689A (en) * 2007-01-18 2007-08-15 中国药科大学 Tumour polypeptide vaccine based on angiotensin II
CA2923980C (en) * 2012-09-13 2020-03-10 British Columbia Cancer Agency Branch Compositions targeting bradykinin receptor b1 for medical imaging of cancer and other disorders
EP3827846A1 (en) * 2015-08-18 2021-06-02 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1901941A (en) * 2003-11-06 2007-01-24 通用电气医疗集团股份有限公司 Conjugates of angiotensin ii and an imaging moiety
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
CN110845572A (en) * 2019-11-28 2020-02-28 中国药科大学 Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. REGOLI ET AL: "The enzymatic degradation of various angiotensin II derivatives by serum, plasma or kidney homogenate", vol. 12, no. 12, pages 637 - 646, XP025486576, DOI: 10.1016/0006-2952(63)90039-X *
MONIQUE COSMAN BALHORN ET AL: "Abstract 1171: Therapeutic applications of the selective highaffinity ligand SH7139 may extend beyond NHL to many othertypes of solid tumors", CANCER RES, vol. 77, pages 1171 *
ROD BALHORN ET AL: "Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia", pages 5621 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116407651A (en) * 2023-05-12 2023-07-11 江西省人民医院 Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine
CN116407651B (en) * 2023-05-12 2024-03-15 江西省人民医院 Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine

Also Published As

Publication number Publication date
CN111558050B (en) 2022-07-15
CN115006553B (en) 2024-01-05
CN115068634A (en) 2022-09-20
CN111558050A (en) 2020-08-21
CN114796528B (en) 2023-11-10
CN115006553A (en) 2022-09-06

Similar Documents

Publication Publication Date Title
CN111558050B (en) Tumor targeting polypeptide and application thereof
CN110845572B (en) Tumor-targeted GRP (glass-fiber reinforced Polypropylene) analogue and application thereof
CN113880917B (en) Tumor high affinity peptides and application thereof
CN114933633B (en) Natural peptide probe for specifically recognizing FGFR4 and application thereof
CN103911017B (en) Cyanine dye compound and preparation method thereof, for dual-use function agent of photodynamic therapy and preparation method thereof
CN111675750B (en) Tumor targeting peptide aiming at carcinoembryonic antigen related adhesion molecule CEACAM and application thereof
CN111344021A (en) Dual-labeled probe for molecular imaging and uses thereof
CN112043839A (en) Radioisotope-labeled polypeptide imaging agent targeting transferrin receptor and application thereof
CN116063379A (en) EphA2 targeting polypeptides and uses thereof
CN115286693A (en) Tumor targeting peptide aiming at carcinoembryonic antigen related cell adhesion molecule CEACAM6 and application thereof
CN114573558A (en) Water-soluble methyl benzyl ether derivative, positron nuclide probe, nuclide marker, preparation method and application
CN112480212A (en) High-affinity peptide of targeted hepatocyte growth factor and application thereof
CN114177314B (en) Application of thymic pentapeptide and its derivative in preparing tumor diagnosis and/or treatment reagent
CN114288426B (en) Application of eribante and derivatives thereof in preparation of tumor diagnosis and/or treatment reagent
CN113813405A (en) Molecular imaging probe based on lisinopril and application thereof
CN115317627B (en) Application of ABT-510 peptide in preparation of tumor imaging agent
WO2023145967A1 (en) Probe for nuclear medical testing
CN115819525A (en) Tumor-targeted typhus toxin B subunit mimic peptide and application thereof
CN116023432A (en) Bissialoganglioside GD2 affinity peptide and application thereof
Chapeau et al. eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors
CN117924419A (en) Affinity peptide of targeted EGF receptor 2 and application thereof
CN117946209A (en) Tumor targeting molecular probe and preparation method and application thereof
TW202327665A (en) New peptide-based diagnostic and therapeutic agents
Batanete Bimodal Probes for Imaging of Prostate Cancer
JP2024501947A (en) Tracer compounds and their preparation methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant